BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37114393)

  • 1. A novel prognostic index for diffuse large B-cell lymphoma combined baseline metabolic tumour volume with clinical and pathological risk factors.
    Yuan T; Chen X; Zhang Y; Wei M; Zhu H; Yang Z; Wang X
    Nucl Med Commun; 2023 Jul; 44(7):622-630. PubMed ID: 37114393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.
    Song MK; Chung JS; Shin HJ; Lee SM; Lee SE; Lee HS; Lee GW; Kim SJ; Lee SM; Chung DS
    Ann Hematol; 2012 May; 91(5):697-703. PubMed ID: 22071570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
    Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
    Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
    Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
    [No Abstract]   [Full Text] [Related]  

  • 9. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
    Mikhaeel NG; Heymans MW; Eertink JJ; de Vet HCW; Boellaard R; Dührsen U; Ceriani L; Schmitz C; Wiegers SE; Hüttmann A; Lugtenburg PJ; Zucca E; Zwezerijnen GJC; Hoekstra OS; Zijlstra JM; Barrington SF
    J Clin Oncol; 2022 Jul; 40(21):2352-2360. PubMed ID: 35357901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
    Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
    Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI.
    Xu H; Ma J; Yang G; Xiao S; Li W; Sun Y; Sun Y; Wang Z; Zhao H
    Eur J Radiol; 2023 Jun; 163():110798. PubMed ID: 37030099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction nomogram based on 18F-FDG PET/CT and clinical parameters for patients with diffuse large B-cell lymphoma.
    Peng X; Yu S; Kou Y; Dang J; Wu P; Yao Y; Shen J; Liu Y; Wang X; Cheng Z
    Ann Hematol; 2023 Nov; 102(11):3115-3124. PubMed ID: 37400729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of
    Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
    Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
    Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.